Neko Health raises $260m for its bid to transform healthcare

Neko Health founders Hjalmar Nilsonne (l) and Daniel Ek (r).
The new business venture of Spotify founder Daniel Ek – Neko Health – has raised $260 million to bring its full body-scanning technology to markets around the world.
Neko Health was co-founded by Ek and Swedish entrepreneur Hjalmar Nilsonne in 2018 to launch clinics offering preventive health checks using dozens of different sensors to map millions of health data points in the body to spot signs of developing illness.
It uses high-resolution 2D and 3D photography and thermal imaging, alongside cardiovascular measurements, grip strength, eye pressure assessment, and blood tests to generate data that is then assessed by AI and generates a report that is available to the customer within minutes.
The scan – which is followed by a doctor consultation – checks moles and marks on the skin, looks for symptoms of metabolic syndrome, and risk factors for stroke and heart attack, and also measures blood sugar to assess pre-diabetes risk. Additionally, it checks for skin cancer and blood abnormalities, according to Neko, which says the entire process takes around an hour.
The first clinics opened in London, UK, and Stockholm in Sweden, starting in 2023, and since then around 10,000 scans have been carried out at a cost to the patient of £299 (around $370) and 2,750 krona (about $250), respectively.
Another 100,000 people are on a waiting list for the scans, according to the company, which claims that, on average, 80% of customers book and prepay a scan for the following year at the end of their appointment. The one-off fee also covers follow-up on any concerns raised by the scanning process.
According to Nilsonne, Neko Health has emerged "at the beginning of a big shift of the healthcare market, from reactive to proactive, driven both by technological advancements and growing consumer demand."
The new cash will be used to expand into other markets, including other countries in Europe and the US, and to invest in R&D, added the CEO.
Lightspeed's Bejul Somaia, who is joining Neko Health's board following the investment round, said that the company founders are "not just building another healthcare company – they [are] fundamentally rethinking how we approach prevention."
The Series B – which has raised Neko Health's valuation to around $1.7 billion, according to the Financial Times – was led by Lightspeed Venture Partners, with participation from General Catalyst, OG Venture Partners, Rosello, Lakestar, and Atomico. It follows a $65 million first round that closed in 2023.